Evidence map›Paper›PMID 32372207›Full record

ArticleDiabetologia2020

Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes.

Cindy Gueguen, Sandra L Burke, Benjamin Barzel, Nina Eikelis, Anna M D Watson, Jay C Jha, Kristy L Jackson, Yusuke Sata, Kyungjoon Lim, Gavin W Lambert and 4 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Cindy GueguenNeuropharmacology Laboratory, Baker Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC, 3004, Australia.
Sandra L BurkeNeuropharmacology Laboratory, Baker Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC, 3004, Australia.
Benjamin BarzelNeuropharmacology Laboratory, Baker Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC, 3004, Australia.
Nina EikelisIverson Health Innovation Research Institute and School of Health Science, Swinburne University of Technology, Melbourne, VIC, Australia.
Anna M D WatsonDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Jay C JhaDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Kristy L JacksonNeuropharmacology Laboratory, Baker Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC, 3004, Australia.
Yusuke SataNeuropharmacology Laboratory, Baker Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC, 3004, Australia.
Kyungjoon LimNeuropharmacology Laboratory, Baker Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC, 3004, Australia.
Gavin W LambertIverson Health Innovation Research Institute and School of Health Science, Swinburne University of Technology, Melbourne, VIC, Australia.
Karin A M Jandeleit-DahmDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Mark E CooperDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Merlin C ThomasDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Geoffrey A HeadNeuropharmacology Laboratory, Baker Heart and Diabetes Institute, P.O. Box 6492, Melbourne, VIC, 3004, Australia. geoff.head@baker.edu.au.ORCID 0000-0002-7623-137X
Baker Heart and Diabetes Institute · AUMonash University · AUSwinburne University of Technology · AUDeutsches Diabetes-Zentrum e.V. · DE

Funding

Boehringer Ingelheim IIS-02-058National Health and Medical Research Council GNT1079645
6 · The paper itself

Abstract

aims/hypothesisWe determined whether empagliflozin altered renal sympathetic nerve activity (RSNA) and baroreflexes in a diabetes model in conscious rabbits.

methodsDiabetes was induced by alloxan, and RSNA, mean arterial pressure (MAP) and heart rate were measured before and after 1 week of treatment with empagliflozin, insulin, the diuretic acetazolamide or the ACE inhibitor perindopril, or no treatment, in conscious rabbits.

resultsFour weeks after alloxan administration, blood glucose was threefold and MAP 9% higher than non-diabetic controls (p < 0.05). One week of treatment with empagliflozin produced a stable fall in blood glucose (-43%) and increased water intake (+49%) but did not change RSNA, MAP or heart rate compared with untreated diabetic rabbits. The maximum RSNA to hypotension was augmented by 75% (p < 0.01) in diabetic rabbits but the heart rate baroreflex was unaltered. Empagliflozin and acetazolamide reduced the augmentation of the RSNA baroreflex (p < 0.05) to be similar to the non-diabetic group. Noradrenaline (norepinephrine) spillover was similar in untreated diabetic and non-diabetic rabbits but twofold greater in empagliflozin- and acetazolamide-treated rabbits (p < 0.05). CONCLUSIONS/

interpretationAs empagliflozin can restore diabetes-induced augmented sympathetic reflexes, this may be beneficial in diabetic patients. A similar action of the diuretic acetazolamide suggests that the mechanism may involve increased sodium and water excretion. Graphical abstract.

Indexed as

AnimalsBaroreflexBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightGlucosidesHeart RateMalePerindoprilRabbitsSodium-Glucose Transporter 2 InhibitorsSympathetic Nervous SystemBenzhydryl CompoundsBlood GlucoseempagliflozinGlucosidesPerindoprilSodium-Glucose Transporter 2 InhibitorsBaroreflexDiabetesEmpagliflozinPerindoprilRenal sympathetic nerve activitySGLT2 inhibitor

Identifiers

PMID32372207
OpenAlexW3021373499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.